Analyze variant(s)

Welcome to the Genetic Therapy Generator Toolkit, please specify one or more variants in a single HGVS description below:

Examples

The input must be an allele in HGVS format, describing variants on an Ensembl transcript.

Variant Explanation
ENST00000375549.8:c.100del Frameshift deletion in exon 2 of SHDH
NC_000023.11(NM_004006.3):c.2500del Frameshift deletion in exon 20 of DMD

Analysis results for NC_000023.11(NM_004006.3):c.2504_2505delinsAG

GTGT analysis results for both the input variants and the wildtype version of the transcript. By definition, the Remaining percentage of the wildtype transcript is always 100%.

Input
arrow_drop_down
Variant description

DNA: NC_000023.11(NM_004006.3):c.2504_2505delinsAG

RNA: NC_000023.11(NM_004006.3):r.2504_2505delinsAG

Protein: NC_000023.11(NP_003997.2):p.(Phe835Ter)

Therapy description

The annotations based on the supplied input variants.

Transcript visualization
Visualization of the input variants and exons (with reading frames), generated with ExonViz. 12345667891011121314151617181920202122232425262728293031323333343536373839404142424344454647484950515152535455565758596061626364656667686970717273747576777879797979c.2504_2505delinsAG
Changed annotations
Annotation Remaining Basepairs Percentage
Exons 100.0% 13990/13992
Coding exons 22.7% 2505/11058
zinc finger: ZZ-type; degenerate 0.0% 0/171
WW: WW 0.0% 0/102
repeat: Spectrin 24 0.0% 0/318
repeat: Spectrin 23 0.0% 0/369
repeat: Spectrin 22 0.0% 0/342
repeat: Spectrin 21 0.0% 0/321
repeat: Spectrin 20 0.0% 0/309
repeat: Spectrin 19 0.0% 0/315
repeat: Spectrin 18 0.0% 0/324
repeat: Spectrin 17 0.0% 0/315
repeat: Spectrin 16 0.0% 0/330
repeat: Spectrin 15 0.0% 0/309
repeat: Spectrin 14 0.0% 0/288
repeat: Spectrin 13 0.0% 0/300
repeat: Spectrin 12 0.0% 0/318
repeat: Spectrin 11 0.0% 0/303
repeat: Spectrin 10 0.0% 0/288
repeat: Spectrin 9 0.0% 0/306
repeat: Spectrin 8 0.0% 0/321
repeat: Spectrin 7 0.0% 0/321
repeat: Spectrin 6 0.0% 0/309
repeat: Spectrin 5 4.8% 15/315
helix 61.5% 732/1191
turn 47.6% 30/63
beta 25.0% 30/120
biased: Polar residues 0.0% 0/213
bind 0.0% 0/12
phos: Phosphoserine 18.2% 6/33
1 22.6% 2502/11055
Disordered: Disordered 0.0% 0/330
Binds to SNTB1: Binds to SNTB1 0.0% 0/159
Int:SYNM: Interaction with SYNM 0.0% 0/2550
Unchanged annotations arrow_drop_down
Annotation Remaining Basepairs Percentage
Calponin-homol...: Calponin-homology (CH) 2 100.0% 321/321
Calponin-homol...: Calponin-homology (CH) 1 100.0% 315/315
repeat: Spectrin 4 100.0% 330/330
repeat: Spectrin 3 100.0% 327/327
repeat: Spectrin 2 100.0% 327/327
repeat: Spectrin 1 100.0% 327/327
phos: Phosphothreonine 100.0% 12/12
Actin-binding: Actin-binding 100.0% 720/720
ANK2- and ANK-...: ANK2- and ANK-3 binding 100.0% 30/30
Wildtype
arrow_drop_down
Variant description

DNA: NC_000023.11(NM_004006.3):c.=

RNA: NC_000023.11(NM_004006.3):r.=

Protein: NC_000023.11(NP_003997.2):p.(=)

Therapy description

These are the annotations as defined on the reference. They are always 100% by definition.

Unchanged annotations arrow_drop_down
Annotation Remaining Basepairs Percentage
Exons 100.0% 13992/13992
Coding exons 100.0% 11058/11058
zinc finger: ZZ-type; degenerate 100.0% 171/171
WW: WW 100.0% 102/102
Calponin-homol...: Calponin-homology (CH) 2 100.0% 321/321
Calponin-homol...: Calponin-homology (CH) 1 100.0% 315/315
repeat: Spectrin 24 100.0% 318/318
repeat: Spectrin 23 100.0% 369/369
repeat: Spectrin 22 100.0% 342/342
repeat: Spectrin 21 100.0% 321/321
repeat: Spectrin 20 100.0% 309/309
repeat: Spectrin 19 100.0% 315/315
repeat: Spectrin 18 100.0% 324/324
repeat: Spectrin 17 100.0% 315/315
repeat: Spectrin 16 100.0% 330/330
repeat: Spectrin 15 100.0% 309/309
repeat: Spectrin 14 100.0% 288/288
repeat: Spectrin 13 100.0% 300/300
repeat: Spectrin 12 100.0% 318/318
repeat: Spectrin 11 100.0% 303/303
repeat: Spectrin 10 100.0% 288/288
repeat: Spectrin 9 100.0% 306/306
repeat: Spectrin 8 100.0% 321/321
repeat: Spectrin 7 100.0% 321/321
repeat: Spectrin 6 100.0% 309/309
repeat: Spectrin 5 100.0% 315/315
repeat: Spectrin 4 100.0% 330/330
repeat: Spectrin 3 100.0% 327/327
repeat: Spectrin 2 100.0% 327/327
repeat: Spectrin 1 100.0% 327/327
helix 100.0% 1191/1191
turn 100.0% 63/63
beta 100.0% 120/120
biased: Polar residues 100.0% 213/213
bind 100.0% 12/12
phos: Phosphoserine 100.0% 33/33
phos: Phosphothreonine 100.0% 12/12
1 100.0% 11055/11055
Disordered: Disordered 100.0% 330/330
Binds to SNTB1: Binds to SNTB1 100.0% 159/159
Int:SYNM: Interaction with SYNM 100.0% 2550/2550
Actin-binding: Actin-binding 100.0% 720/720
ANK2- and ANK-...: ANK2- and ANK-3 binding 100.0% 30/30

Variant-modifying therapies

This section contains analysis results for therapies which directly modify or remove the specified input variants.

Skip exons 19 and 20
arrow_drop_down
Variant description

DNA: NM_004006.3:c.2293_2622del

RNA: NM_004006.3:r.2293_2622del

Protein: NC_000023.11(NP_003997.2):p.(Ala765_Lys874del)

Therapy description

The annotations based on the supplied variants, in combination with skipping exons 19 and 20.

Changed annotations
Annotation Remaining Basepairs Percentage
Exons 97.6% 13662/13992
Coding exons 97.0% 10728/11058
repeat: Spectrin 5 57.1% 180/315
repeat: Spectrin 4 41.8% 138/330
1 97.0% 10725/11055
Unchanged annotations arrow_drop_down
Annotation Remaining Basepairs Percentage
zinc finger: ZZ-type; degenerate 100.0% 171/171
WW: WW 100.0% 102/102
Calponin-homol...: Calponin-homology (CH) 2 100.0% 321/321
Calponin-homol...: Calponin-homology (CH) 1 100.0% 315/315
repeat: Spectrin 24 100.0% 318/318
repeat: Spectrin 23 100.0% 369/369
repeat: Spectrin 22 100.0% 342/342
repeat: Spectrin 21 100.0% 321/321
repeat: Spectrin 20 100.0% 309/309
repeat: Spectrin 19 100.0% 315/315
repeat: Spectrin 18 100.0% 324/324
repeat: Spectrin 17 100.0% 315/315
repeat: Spectrin 16 100.0% 330/330
repeat: Spectrin 15 100.0% 309/309
repeat: Spectrin 14 100.0% 288/288
repeat: Spectrin 13 100.0% 300/300
repeat: Spectrin 12 100.0% 318/318
repeat: Spectrin 11 100.0% 303/303
repeat: Spectrin 10 100.0% 288/288
repeat: Spectrin 9 100.0% 306/306
repeat: Spectrin 8 100.0% 321/321
repeat: Spectrin 7 100.0% 321/321
repeat: Spectrin 6 100.0% 309/309
repeat: Spectrin 3 100.0% 327/327
repeat: Spectrin 2 100.0% 327/327
repeat: Spectrin 1 100.0% 327/327
helix 100.0% 1191/1191
turn 100.0% 63/63
beta 100.0% 120/120
biased: Polar residues 100.0% 213/213
bind 100.0% 12/12
phos: Phosphoserine 100.0% 33/33
phos: Phosphothreonine 100.0% 12/12
Disordered: Disordered 100.0% 330/330
Binds to SNTB1: Binds to SNTB1 100.0% 159/159
Int:SYNM: Interaction with SYNM 100.0% 2550/2550
Actin-binding: Actin-binding 100.0% 720/720
ANK2- and ANK-...: ANK2- and ANK-3 binding 100.0% 30/30
Skip exons 20 and 21
arrow_drop_down
Variant description

DNA: NM_004006.3:c.2381_2803del

RNA: NM_004006.3:r.2381_2803del

Protein: NC_000023.11(NP_003997.2):p.(Glu794_Ile935delinsVal)

Therapy description

The annotations based on the supplied variants, in combination with skipping exons 20 and 21.

Changed annotations
Annotation Remaining Basepairs Percentage
Exons 97.0% 13569/13992
Coding exons 96.1% 10632/11058
repeat: Spectrin 5 0.0% 0/315
repeat: Spectrin 4 68.2% 225/330
1 96.1% 10629/11055
Unchanged annotations arrow_drop_down
Annotation Remaining Basepairs Percentage
zinc finger: ZZ-type; degenerate 100.0% 171/171
WW: WW 100.0% 102/102
Calponin-homol...: Calponin-homology (CH) 2 100.0% 321/321
Calponin-homol...: Calponin-homology (CH) 1 100.0% 315/315
repeat: Spectrin 24 100.0% 318/318
repeat: Spectrin 23 100.0% 369/369
repeat: Spectrin 22 100.0% 342/342
repeat: Spectrin 21 100.0% 321/321
repeat: Spectrin 20 100.0% 309/309
repeat: Spectrin 19 100.0% 315/315
repeat: Spectrin 18 100.0% 324/324
repeat: Spectrin 17 100.0% 315/315
repeat: Spectrin 16 100.0% 330/330
repeat: Spectrin 15 100.0% 309/309
repeat: Spectrin 14 100.0% 288/288
repeat: Spectrin 13 100.0% 300/300
repeat: Spectrin 12 100.0% 318/318
repeat: Spectrin 11 100.0% 303/303
repeat: Spectrin 10 100.0% 288/288
repeat: Spectrin 9 100.0% 306/306
repeat: Spectrin 8 100.0% 321/321
repeat: Spectrin 7 100.0% 321/321
repeat: Spectrin 6 100.0% 309/309
repeat: Spectrin 3 100.0% 327/327
repeat: Spectrin 2 100.0% 327/327
repeat: Spectrin 1 100.0% 327/327
helix 100.0% 1191/1191
turn 100.0% 63/63
beta 100.0% 120/120
biased: Polar residues 100.0% 213/213
bind 100.0% 12/12
phos: Phosphoserine 100.0% 33/33
phos: Phosphothreonine 100.0% 12/12
Disordered: Disordered 100.0% 330/330
Binds to SNTB1: Binds to SNTB1 100.0% 159/159
Int:SYNM: Interaction with SYNM 100.0% 2550/2550
Actin-binding: Actin-binding 100.0% 720/720
ANK2- and ANK-...: ANK2- and ANK-3 binding 100.0% 30/30
Skip exon 20
arrow_drop_down
Variant description

DNA: NM_004006.3:c.2381_2622del

RNA: NM_004006.3:r.2381_2622del

Protein: NC_000023.11(NP_003997.2):p.(Glu794GlyfsTer2)

Therapy description

The annotations based on the supplied variants, in combination with skipping exon 20.

Changed annotations
Annotation Remaining Basepairs Percentage
Exons 98.3% 13750/13992
Coding exons 21.5% 2382/11058
zinc finger: ZZ-type; degenerate 0.0% 0/171
WW: WW 0.0% 0/102
repeat: Spectrin 24 0.0% 0/318
repeat: Spectrin 23 0.0% 0/369
repeat: Spectrin 22 0.0% 0/342
repeat: Spectrin 21 0.0% 0/321
repeat: Spectrin 20 0.0% 0/309
repeat: Spectrin 19 0.0% 0/315
repeat: Spectrin 18 0.0% 0/324
repeat: Spectrin 17 0.0% 0/315
repeat: Spectrin 16 0.0% 0/330
repeat: Spectrin 15 0.0% 0/309
repeat: Spectrin 14 0.0% 0/288
repeat: Spectrin 13 0.0% 0/300
repeat: Spectrin 12 0.0% 0/318
repeat: Spectrin 11 0.0% 0/303
repeat: Spectrin 10 0.0% 0/288
repeat: Spectrin 9 0.0% 0/306
repeat: Spectrin 8 0.0% 0/321
repeat: Spectrin 7 0.0% 0/321
repeat: Spectrin 6 0.0% 0/309
repeat: Spectrin 5 0.0% 0/315
repeat: Spectrin 4 68.2% 225/330
helix 61.5% 732/1191
turn 47.6% 30/63
beta 25.0% 30/120
biased: Polar residues 0.0% 0/213
bind 0.0% 0/12
phos: Phosphoserine 18.2% 6/33
1 21.5% 2379/11055
Disordered: Disordered 0.0% 0/330
Binds to SNTB1: Binds to SNTB1 0.0% 0/159
Int:SYNM: Interaction with SYNM 0.0% 0/2550
Unchanged annotations arrow_drop_down
Annotation Remaining Basepairs Percentage
Calponin-homol...: Calponin-homology (CH) 2 100.0% 321/321
Calponin-homol...: Calponin-homology (CH) 1 100.0% 315/315
repeat: Spectrin 3 100.0% 327/327
repeat: Spectrin 2 100.0% 327/327
repeat: Spectrin 1 100.0% 327/327
phos: Phosphothreonine 100.0% 12/12
Actin-binding: Actin-binding 100.0% 720/720
ANK2- and ANK-...: ANK2- and ANK-3 binding 100.0% 30/30

Other therapies

This section contains therapies which do not directly change any of the specified input variants.

Skip exon 19
arrow_drop_down
Variant description

DNA: NM_004006.3:c.[2293_2380del;2504_2505delinsAG]

RNA: NM_004006.3:r.[2293_2380del;2504_2505delinsAG]

Protein: NC_000023.11(NP_003997.2):p.Ala765_Met3685delinsArgValLeuMetGlnIleAlaSerAsnLysProGlnAsnAsn

Therapy description

The annotations based on the supplied variants, in combination with skipping exon 19.

Changed annotations
Annotation Remaining Basepairs Percentage
Exons 99.4% 13902/13992
Coding exons 21.1% 2331/11058
zinc finger: ZZ-type; degenerate 0.0% 0/171
WW: WW 0.0% 0/102
repeat: Spectrin 24 0.0% 0/318
repeat: Spectrin 23 0.0% 0/369
repeat: Spectrin 22 0.0% 0/342
repeat: Spectrin 21 0.0% 0/321
repeat: Spectrin 20 0.0% 0/309
repeat: Spectrin 19 0.0% 0/315
repeat: Spectrin 18 0.0% 0/324
repeat: Spectrin 17 0.0% 0/315
repeat: Spectrin 16 0.0% 0/330
repeat: Spectrin 15 0.0% 0/309
repeat: Spectrin 14 0.0% 0/288
repeat: Spectrin 13 0.0% 0/300
repeat: Spectrin 12 0.0% 0/318
repeat: Spectrin 11 0.0% 0/303
repeat: Spectrin 10 0.0% 0/288
repeat: Spectrin 9 0.0% 0/306
repeat: Spectrin 8 0.0% 0/321
repeat: Spectrin 7 5.6% 18/321
repeat: Spectrin 6 0.0% 0/309
repeat: Spectrin 5 4.8% 15/315
repeat: Spectrin 4 42.7% 141/330
helix 61.5% 732/1191
turn 47.6% 30/63
beta 25.0% 30/120
biased: Polar residues 0.0% 0/213
bind 0.0% 0/12
phos: Phosphoserine 18.2% 6/33
1 21.1% 2328/11055
Disordered: Disordered 0.0% 0/330
Binds to SNTB1: Binds to SNTB1 0.0% 0/159
Int:SYNM: Interaction with SYNM 0.0% 0/2550
Unchanged annotations arrow_drop_down
Annotation Remaining Basepairs Percentage
Calponin-homol...: Calponin-homology (CH) 2 100.0% 321/321
Calponin-homol...: Calponin-homology (CH) 1 100.0% 315/315
repeat: Spectrin 3 100.0% 327/327
repeat: Spectrin 2 100.0% 327/327
repeat: Spectrin 1 100.0% 327/327
phos: Phosphothreonine 100.0% 12/12
Actin-binding: Actin-binding 100.0% 720/720
ANK2- and ANK-...: ANK2- and ANK-3 binding 100.0% 30/30
Skip exons 12 and 13
arrow_drop_down
Variant description

DNA: NM_004006.3:c.[1332_1602del;2504_2505delinsAG]

RNA: NM_004006.3:r.[1332_1602del;2504_2505delinsAG]

Protein: NC_000023.11(NP_003997.2):p.Asn444_Met3685delinsLysTyrTrpGluIleAspGlyGlnThrSerValAspGlyGlnLysThrAlaGlyPhePheTyrLysThrSerPheSerAsnGlyAsnValLeuLeuLysAsnSerAlaPheLeuValHisGlyPheGlnLysLysLysMetGln

Therapy description

The annotations based on the supplied variants, in combination with skipping exons 12 and 13.

Changed annotations
Annotation Remaining Basepairs Percentage
Exons 98.0% 13719/13992
Coding exons 13.3% 1473/11058
zinc finger: ZZ-type; degenerate 0.0% 0/171
WW: WW 0.0% 0/102
repeat: Spectrin 24 0.0% 0/318
repeat: Spectrin 23 0.0% 0/369
repeat: Spectrin 22 0.0% 0/342
repeat: Spectrin 21 0.0% 0/321
repeat: Spectrin 20 0.0% 0/309
repeat: Spectrin 19 0.0% 0/315
repeat: Spectrin 18 0.0% 0/324
repeat: Spectrin 17 0.0% 0/315
repeat: Spectrin 16 0.0% 0/330
repeat: Spectrin 15 0.0% 0/309
repeat: Spectrin 14 0.0% 0/288
repeat: Spectrin 13 7.0% 21/300
repeat: Spectrin 12 0.0% 0/318
repeat: Spectrin 11 3.0% 9/303
repeat: Spectrin 10 5.2% 15/288
repeat: Spectrin 9 4.9% 15/306
repeat: Spectrin 8 5.6% 18/321
repeat: Spectrin 7 2.8% 9/321
repeat: Spectrin 6 2.9% 9/309
repeat: Spectrin 5 7.6% 24/315
repeat: Spectrin 4 1.8% 6/330
repeat: Spectrin 3 3.7% 12/327
repeat: Spectrin 2 0.0% 0/327
repeat: Spectrin 1 96.3% 315/327
helix 59.2% 705/1191
turn 47.6% 30/63
beta 25.0% 30/120
biased: Polar residues 0.0% 0/213
bind 0.0% 0/12
phos: Phosphoserine 18.2% 6/33
phos: Phosphothreonine 25.0% 3/12
1 13.3% 1470/11055
Disordered: Disordered 0.0% 0/330
Binds to SNTB1: Binds to SNTB1 0.0% 0/159
Int:SYNM: Interaction with SYNM 1.8% 45/2550
Unchanged annotations arrow_drop_down
Annotation Remaining Basepairs Percentage
Calponin-homol...: Calponin-homology (CH) 2 100.0% 321/321
Calponin-homol...: Calponin-homology (CH) 1 100.0% 315/315
Actin-binding: Actin-binding 100.0% 720/720
ANK2- and ANK-...: ANK2- and ANK-3 binding 100.0% 30/30
External resources
Export report

Here will be an option to export the report, either as a stand alone html page or a PDF document

Documentation
Introduction

The Genetic Therapy Generator Toolkit helps users determine whether a given variant (or set of variants) can be corrected with a genetic therapy. Rather than relying on explicit guidelines about which kinds of variants can be treated, GTGT simulates the effect of every possible therapy and ranks the therapies based on how many of the transcript features are restored.

Because of this unique approach, GTGT can identify possible therapies when it appears none are available, for example by skipping upstream or downstream exons to restore the reading frame, or by skipping adjacent exons (experimental).

Interpreting results

The first two entries on the results page will always be the analysis of the Wildtype and Input versions of the transcript. Each entry contains the name, HGVS notation and short description of the therapy. The most important section is the Annotation overview, which lists the percentage of each feature of the transcript that remains after the mutations (and therapy) have been applied. The Exons feature refers to all bases that make up the exon. When GTGT skips an exon, the bases of the exon will be removed from the Exons feature, which can be seen from the percentage and the remaining basepairs. The Coding exons refer to the bases that make up the coding sequence of the transcript. Changes in the Coding exons take the actual predicted protein changes in the transcript into account. For example, in the case of a frameshift variant all bases after the frameshift will be removed from the Coding exons feature, but not from the Exons.

The extended documentation for this tool can be found on https://gtgt.readthedocs.io.

Development

The Genetic Therapy Generator Toolkit has been developed by the Dutch Center for RNA Therapeutics, who have committed to continue to fund the development of GTGT until at least June 2027.

GTGT can be installed locally via PyPi, or you can install the development version from Github. We welcome contributions, bug reports and other feedback on GitHub or via an email to DCRT@LUMC.nl.

GTGT is free to use and redistribute under the conditions of the GNU Affero General Public License v3.0.

Disclaimer

Copyright© 2023 LUMC https://www.lumc.nl

This program is free software: you can redistribute it and/or modify it under the terms of the GNU Affero General Public License as published by the Free Software Foundation, either version 3 of the License, or (at your option) any later version.

This program is distributed in the hope that it will be useful, but WITHOUT ANY WARRANTY; without even the implied warranty of MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See the GNU Affero General Public License for more details.

By accessing and using the program in any manner (including copying, modifying or redistributing the program), you accept and agree to the applicability of the GNU Affero General Public License. You can find and read this license on GNU Affero General Public License - GNU Project - Free Software Foundation.